美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Evommune

27.88

-0.5800-2.04%

盘前：29.441.56+5.60%08:42 EST

成交量：55.39万

成交额：1,551.46万

市值：8.79亿

市盈率：-13.99

高：30.68

开：27.70

低：26.42

收：28.46

52周最高：33.20

52周最低：13.89

股本：3,152.41万

流通股本：940.00万

量比：0.16

换手率：5.89%

股息：- -

股息率：- -

每股收益(TTM):-1.9930

每股收益(LYR):-45.2873

净资产收益率：--

总资产收益率：--

市净率：-4.80

市盈率(LYR):-0.62

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Evommune, Inc.盘中异动大幅跳水5.09%报27.01美元

BUZZ-湿疹疗法在中期试验中表现良好，Evommune业绩大涨

Evommune公司：同时评估Evo301的潜在新增适应症，包括溃疡性结肠炎

Evommune公布Evo301治疗中重度特应性皮炎二期a期概念验证试验积极顶线数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/EVMN"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":27.88,"timestamp":1770930000000,"preClose":28.46,"halted":0,"volume":553949,"hourTrading":{"tag":"盘前","latestPrice":29.44,"preClose":27.88,"latestTime":"08:42 EST","volume":2575,"amount":75360.266725,"timestamp":1770990145688,"change":1.56,"changeRate":0.055954,"amplitude":0.04089},"delay":0,"changeRate":-0.020379479971890435,"floatShares":9400000,"shares":31524093,"eps":-1.993,"marketStatus":"盘前交易","change":-0.58,"latestTime":"02-13 08:44:36 EST","open":27.7,"high":30.68,"low":26.42,"amount":15514589.238148,"amplitude":0.149684,"askPrice":29.8,"askSize":2,"bidPrice":28.51,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-1.993,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770993000000},"marketStatusCode":1,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":27.88,"preHourTrading":{"tag":"盘前","latestPrice":29.44,"preClose":27.88,"latestTime":"08:42 EST","volume":2575,"amount":75360.266725,"timestamp":1770990145688,"change":1.56,"changeRate":0.055954,"amplitude":0.04089},"postHourTrading":{"tag":"盘后","latestPrice":28.88,"preClose":27.88,"latestTime":"19:59 EST","volume":1922,"amount":53420.7978,"timestamp":1770944365559,"change":1,"changeRate":0.035868,"amplitude":0.062052},"volumeRatio":0.15502179642260394},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":9400000,"roa":"--","roe":"--","lyrEps":-45.287292,"volumeRatio":0.15502179642260394,"shares":31524093,"dividePrice":0,"high":30.68,"amplitude":0.149684,"preClose":28.46,"low":26.42,"week52Low":13.885,"pbRate":"-4.80","psRate":"67.61","week52High":33.2,"institutionHeld":0,"latestPrice":27.88,"committee":0.764706,"eps":-1.993,"divideRate":0,"volume":553949,"delay":0,"ttmEps":-1.993,"open":27.7,"prevYearClose":17.12,"prevWeekClose":17.31,"prevMonthClose":18.1,"prevQuarterClose":17.12,"fiveDayClose":16.66,"twentyDayClose":21.25,"sixtyDayClose":18.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1769144400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-02-12","current":-13.988961,"percent":0.014493,"low":-14.923347,"twenty":-9.861058,"median":-9.064213,"eighty":-8.561079,"high":-7.430686,"avg":-9.316818,"sd":1.250364,"marketCap":897175686},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-12","current":-14.630329,"twenty":-9.861058,"median":-9.064213,"eighty":-8.561079,"marketCap":897175686}],"updateTime":1770978272594},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611901796","title":"Evommune, Inc.盘中异动 大幅跳水5.09%报27.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611901796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611901796?lang=zh_cn&edition=fundamental","pubTime":"2026-02-12 22:32","pubTimestamp":1770906774,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时32分，Evommune, Inc.股票出现波动，股价快速跳水5.09%。截至发稿，该股报27.01美元/股，成交量2.4506万股，换手率0.08%，振幅2.16%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2610062539","title":"BUZZ-湿疹疗法在中期试验中表现良好，Evommune业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2610062539","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610062539?lang=zh_cn&edition=fundamental","pubTime":"2026-02-10 21:52","pubTimestamp":1770731563,"startTime":"0","endTime":"0","summary":"BUZZ-湿疹疗法在中期试验中表现良好，Evommune业绩大涨2月10日 - ** 药物开发商Evommune EVMN.N 股价盘前大涨102.47%，至33.8美元 ** 该公司称  其试验性疗法 EVO301 在中重度特应性皮炎患者中的测试达到了中期试验的主要目标。** 特应性皮炎或湿疹是一种慢性皮肤病，由于皮肤屏障缺陷和过度活跃的免疫反应，会导致皮肤干燥、发痒、发炎。** 在一项有 70 名患者参加的试验中，与服用安慰剂的患者相比，服用 EVO301 的患者中有 23% 的人皮肤状况清晰或接近清晰，并有明显改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4T3Z61KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"1168920254","title":"Evommune公司：同时评估Evo301的潜在新增适应症，包括溃疡性结肠炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1168920254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168920254?lang=zh_cn&edition=fundamental","pubTime":"2026-02-10 20:32","pubTimestamp":1770726755,"startTime":"0","endTime":"0","summary":"Evommune公司正在对Evo301的潜在新增适应症展开评估，其中溃疡性结肠炎是重点考察方向之一。这一举措旨在拓宽该药物的应用范围，为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"1100113507","title":"Evommune公布Evo301治疗中重度特应性皮炎二期a期概念验证试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113507","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100113507?lang=zh_cn&edition=fundamental","pubTime":"2026-02-10 20:31","pubTimestamp":1770726682,"startTime":"0","endTime":"0","summary":"生物制药公司Evommune近日宣布，其研发的候选药物Evo301在中重度特应性皮炎患者中开展的二期a期概念验证试验获得积极顶线结果。\n该试验数据表明Evo301在主要疗效终点上表现出显著改善，验证了其治疗潜力。这项突破为后续临床开发奠定了坚实基础，有望为特应性皮炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EVMN\",params:#limit:6,delay:false,,,undefined,":[]}}